Docket No. 4439-4047

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No.: 10/599,479 Confirmation No.: 9587

Applicant(s): Masayoshi SHICHIRI Group Art Unit: TBA

Examiner: TBA

Filed: Sept. 29, 2006

Customer No.: 27123

For: Cardioinhibitory/ Antihypertensive Novel Endogenous Physiologically Active Peptide

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This Supplemental Information Disclosure Statement is filed in accordance with 37 C.F.R. §§1.56, 1.97 and 1.98. The items listed on Form PTO-1449, a copy of which is enclosed, are made of record to assist the Patent and Trademark Office in its examination of this application. The Examiner is respectfully requested to fully consider the items and to independently ascertain their teaching.

This document is being filed prior to a first Office Action.

This document is accompanied by an English translation of the International Preliminary Report on Patentability in accordance with Chapter I of the Patent Cooperation Treaty (PCT) in corresponding PCT/JP2005/006510 dated October 19, 2006.

The Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 13-4500, Order No. 4439-4047.

Respectfully submitted,

MORGAN & FINNEGAN, L.L.P.

Dated: January 5, 2007

Evelyn M. Kwon

Registration No. 54,246

Correspondence Address:

MORGAN & FINNEGAN, L.L.P. (212) 415-8700 Telephone 3 World Financial Center (212) 415-8701 Facsimile New York, NY 10281-2101

By:

SUPPLEMENTAL FORM PTO-1449B		Attorney Docket: 4439-4047	Serial No.: 10/599,479			
		Applicant:				
INFO		N DISCLOSURE	Masayoshi SHICHIRI			
CITATION			Filing Date:	Group Art Unit:		
			Sept. 29, 2006	TBA		
			N PATENT DOCUMENTS			
Examiner Initials*	Cite No.1	journal, serial, symposium,	catalog, etc.), date, page(s), volume-i published.			
	1.	International Preliminar Bureau of WIPO, Octob	y Report On Patentability a per 19, 2006, Switzerland co	and Written Opinion The International orresponding to PCT/JP2005/006510.		
De parent integrates continues and a	2.					
	3.	and and the state of the state	A the to when the second comment of the seco			
	4.	Committee of the second committee of the				
	5.					
	6.					
	7.					
	8.	All A de la constant		_		
	9.			*		
	10.					
man ka kanan la Arthur House Tradition and the second second	11.		CANADA CHILI PARI PERI PERI MANGA MANGA CANADA CANA	(Approximate and 1) (Appro		
	12.					
	13.		The state of the s			
	14.					
	15.	Transcript Activities and the second and the second activities activities activities activities and the second activities				
	16.					
	17.					
	18.					
	19.					
	20.					

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant, 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English anguage Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.